1. The use of probiotic bacteria in the manufacture of a medicinal product or therapeutic nutritional composition to stimulate the development of early bifidogenic intestinal microbiota in infants without siblings. ! 2. The use of probiotic bacteria in the manufacture of a medicament or therapeutic nutritional composition to reduce the risk of subsequent development of allergies in infants without siblings. ! 3. The use of probiotic bacteria in the manufacture of a medicament or therapeutic nutritional composition for the prevention or for the treatment of pathogenic infections in infants without siblings. ! 4. The use according to claim 3, in which the pathogenic infection is rotavirus diarrhea. ! 5. The use according to any one of claims 1 to 3, in which the probiotic bacteria are lactic acid bacteria. ! 6. The use of claim 5, wherein the lactic acid bacteria are Lactobacillus rhamnosus ATCC 53103, Lactobacillus rhamnosus CGMCC 1.3724, Lactobacillus reuteri ATCC 55730, Lactobacillus reuteri DSM 17938 or Lactobacillus paracasei CNCM 1-2. ! 7. The use according to any one of claims 1 to 3, in which the probiotic bacteria are bifidobacteria. ! 8. The use according to claim 7, in which the bifidobacteria are strains of Bifidobacterium lactis CNCM 1-3446, Bifidobacterium longum ATCC BAA-999, Bifidobacterium breve Bb-03, Bifidobacterium breve M-16V, Bifidobacterium infantis 35624 or Bifidobacteriumium infantis 35624 or Bifidobacteriumium infantis 35624. ! 9. The use according to any one of claims 1 to 3, in which the drug or therapeutic nutritional composition further comprises a mixture of oligosaccharides, which contains 5-70 wt.%, At least one N-acetylated oligosaccharide selected from the group containing GalNAcα1, 3Galβ1,4Glc and Galβ1,6GalNAcα1,3Galβ1,4Glc, 20-90 wt.%, At least one neutral oligosaccharide selected from the group�1. Применение пробиотических бактерий в производстве лекарственного средства или терапевтической питательной композиции для стимуляции ра
